Hikma Sees Signs Of A Bounceback For Generics

Now Forecasting Generics Sales Growth Of 20% In 2023, After Taking An 18% Hit In 2022

After a tough 2022 that saw Hikma suffer an 18% drop in generics sales – albeit mostly offset by growth in the firm’s injectables and branded divisions – the company has announced fresh forecasts for 2023 that suggest the generics segment will bounce back with growth of a fifth.

Rebound - Arrow Down Then Up
Hikma sees its generics business bouncing back in 2023 • Source: Shutterstock

Hikma has signaled a return to form for its generics business in 2023, forecasting 20% sales growth for the segment after a challenging 2022 that saw the segment’s turnover decline by 18%.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

What’s Next? Five Things To Look Out For In May

 
• By 

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By 

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.

Samsung Bioepis Grows After US Launches

 
• By 

Samsung Bioepis has revealed first-quarter figures that reflect recent launches driving growth for the Korean biosimilars developer.

Despite Multiple Headwinds, Formycon Remains Positive For Its Biosimilars Growth

 

Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By 

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By 

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By 

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.